ZURICH — Deals between pharmaceutical companies and Washington to reduce prices for medicines in the United States will likely push up the cost of new drugs in Switzerland, the CEO of Swiss pharma giant Roche was quoted as saying on Saturday.
Under the deals announced on Friday, drugmakers including Roche’s US unit Genentech will slash prices on drugs sold to the US Medicaid program for low-income people.